Clinical Trial

Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)

Study acronym: PATH
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-06-24; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2022-02-01
Trial Details
NCT Number NCT04448184
Lead Sponsor Ottawa Hospital Research Institute
Collaborators: Alberta Cancer Foundation
Conditions Hematologic Neoplasms
Enrollment 662 participants
Start Date 2022-02-16
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-08